This case-control study using the large organized Japanese claims database provided the risk of upper GI mucosal injuries in patients receiving NSAIDs and antithrombotic drugs.
Our data demonstrate that increasing rabeprazole dose up to 40 mg once daily results in an increasing pharmacodynamic effect, which is most apparent for the control of nocturnal gastric acid secretion.
This study was to examine the recent trends in upper gastro intestinal bleeding in Japan using a large scale real world database. The incidence of upper gastrointestinal bleeding was evaluated in the Japan Medical Data Center claims database of 13,019,713 patients aged 20 to 74 years with traceability for 3 months from 2009 to 2014. The incidence was compared with peptic ulcers and gastroesophageal reflux disease. The prescrip tion of medications was also evaluated. The incidence of bleeding was 0.137%, 0.121%, 0.113%, 0.106%, 0.099%, and 0.105% during 2009 to 2014 with a time dependent decline (p<0.001). Peptic ulcers (>10 times higher than the incidence of bleeding) decreased with time (p<0.001), whereas gastroesophageal reflux disease increased (p = 0.006). Upper gastrointestinal bleeding was higher in male patients and older patients (60-74 years old) (p<0.001 respectively). The prescription rate of antithrombotic medications and proton pump inhibitors increased from 2009 to 2014 (p<0.001 respectively). The incidence of upper gastrointestinal bleeding decreased from 2009 to 2014 in this relatively large scale real world database in Japan, concomitant with the decrease in peptic ulcers. The decreased incidence might have been due to changes in the disease structure and therapeutic strategies over time.
A 24-week, double-blind, clinical trial of rabeprazole for the prevention of
recurrent peptic ulcers caused by low-dose aspirin (LDA) has been reported, but
trials for longer than 24 weeks have not been reported. The aim of this study is to
assess the long-term efficacy and safety of rabeprazole for preventing peptic ulcer
recurrence on LDA therapy. Eligible patients had a history of peptic ulcers on
long-term LDA (81 or 100 mg/day) therapy. Patients with no recurrence of
peptic ulcers at the end of the 24-week double-blind phase with rabeprazole (10- or
5-mg once daily) or teprenone (50 mg three times daily) entered the extension
phase. Rabeprazole doses were maintained for a maximum of 76 weeks, including the
double-blind 24-week period and the extension phase period (long-term rabeprazole 10-
and 5-mg groups). Teprenone was randomly switched to rabeprazole 10 or 5 mg for
a maximum of 52 weeks in the extension phase (newly-initiated rabeprazole 10- and
5-mg groups). The full analysis set consisted of 151 and 150 subjects in the
long-term rabeprazole 10- and 5-mg groups, respectively, and the cumulative
recurrence rates of peptic ulcers were 2.2 and 3.7%, respectively. Recurrent
peptic ulcers were not observed in the newly-initiated rabeprazole 10- and 5-mg
groups. No bleeding ulcers were reported. No clinically significant safety findings,
including cardiovascular events, emerged. The use of long-term rabeprazole 10- and
5-mg once daily prevents the recurrence of peptic ulcers in subjects on low-dose
aspirin therapy, and both were well-tolerated.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.